Tango Therapeutics logo

Senior Director, Medical Affairs Strategy, Oncology

Tango Therapeutics

Boston, MAOnsitePosted 1 day ago$34,000 - $380,000 USD
Full TimeDirector & AboveMedical AffairsBiotechnology
Original posting ↗

Summary

Tango Therapeutics is seeking an experienced Senior Director, Medical Affairs Strategy, Oncology. Reporting to the Executive Director of Medical Affairs, this individual will shape and execute the medical strategy supporting product life-cycle management including registration and launch activities, evidence generation, external expert engagement planning, and patient advocacy partnerships.

Job description

Summary

Tango Therapeutics is seeking an experienced Senior Director, Medical Affairs Strategy, Oncology. Reporting to the Executive Director of Medical Affairs, this individual will shape and execute the medical strategy supporting product life-cycle management including registration and launch activities, evidence generation, external expert engagement planning, and patient advocacy partnerships.

The role will serve as a key strategic partner to Clinical Development, Clinical Operations, Medical Information, Scientific Communications, HEOR/RWE, Biomarkers/Diagnostics, Commercial, Market Access, Regulatory, Safety, Legal, Compliance, and Field Medical to ensure the evidence generated addresses the needs of healthcare professionals, patients, patient advocacy groups, and payers through late-stage development and launch.

Medical Affairs Strategy

  • Lead development and execution of integrated medical affairs plans across oncology programs
  • Lead medical launch-readiness planning, including pre-launch engagement objectives, resource planning, medical education planning, and integration with registrational and post-approval evidence plans
  • Translate clinical development objectives into evidence generation and stakeholder engagement strategies
  • Develop and maintain routine medical plans aligned with corporate objectives

Scientific Leadership

  • Provide scientific leadership, directing medical affairs team members supporting late-stage development, and partnering with Field Medical to translate medical strategy into engagement objectives, resource plans, tactics, and listening priorities that MSLs execute through scientific exchange
  • Ensure scientific consistency across programs and therapeutic areas
  • Define engagement planning objectives, resource plans, tactics, and insight-listening priorities for advisory boards, congress strategy, and external expert engagement, with scientific exchange executed by Field Medical MSLs

Evidence Generation

  • Lead the Medical Affairs evidence-generation strategy through late-stage development and launch
  • Prioritize evidence gaps and develop plans to address scientific and clinical questions arising from late-stage and registrational studies
  • Oversee real-world evidence, outcomes research, and post-approval evidence planning

HEOR and RWE

  • Provide medical input to HEOR and RWE strategies supporting value demonstration, in partnership with the HEOR partners
  • Collaborate with Market Access and Commercial teams to generate evidence relevant to payers and healthcare systems
  • Guide protocol development and data interpretation

IIS and Collaborative Research

  • Develop governance and strategy for investigator-sponsored studies
  • Evaluate research proposals and prioritize the IIS portfolio against late-stage evidence needs
  • Manage external scientific collaborations and academic partnerships
  • Ensure alignment between IIS investments and organizational objectives

Patient Advocacy

  • Build and maintain relationships with patient advocacy organizations, incorporate patient perspectives into medical strategy and evidence planning, and ensure all engagement complies with applicable legal and compliance requirements

Cross-Functional Partnership

  • Partner with Clinical Development to support lifecycle evidence planning
  • Collaborate with Biomarker and Diagnostic teams on precision medicine strategies
  • Work closely with Medical Information, Scientific Communications, and Field Medical teams to ensure coordinated execution, including feeding field insights back into engagement planning

Medical Governance

  • Support medical review and governance activities
  • Ensure compliance with all legal, regulatory, and ethical requirements
  • Contribute to SOP development and medical affairs operating procedures

Requirements

  • MD, PharmD, or PhD in a life sciences discipline; MD preferred
  • 12+ years pharmaceutical/biotech experience
  • 7+ years within oncology Medical Affairs
  • 4+ years of experience in Medical Affairs strategic roles
  • Demonstrated success leading cross-functional initiatives
  • Experience supporting registration-enabling or launch-stage oncology products
  • Strong background in HEOR, RWE, or post-marketing evidence generation
  • Experience partnering and leading in cross-matrix teams, and engaging patient advocacy organizations
  • Precision oncology and biomarker experience
  • Small biotechnology company experience

Company overview

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for cancer treatment. Founded in 2017 and headquartered in Boston, Massachusetts, the company leverages the genetic principle of synthetic lethality to develop targeted therapies that address specific vulnerabilities in cancer cells. Tango's innovative approach focuses on three core areas: counteracting tumor suppressor gene loss, reversing immune evasion mechanisms, and identifying novel combination therapies. The company utilizes advanced DNA sequencing and CRISPR-based target discovery technologies to generate breakthrough medicines with the potential to provide deeper, more sustained benefits than current targeted therapies. Tango's pipeline includes programs for genetically defined subsets of cancers with limited treatment options, with a particular emphasis on expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to cancer cells' ability to evade immune destruction. The company went public in 2021 and continues to advance its clinical programs while maintaining strategic collaborations with pharmaceutical partners.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.